Oragenics (OGEN) News Today $1.12 +0.02 (+1.67%) Closing price 03:59 PM EasternExtended Trading$1.10 -0.02 (-2.09%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OGEN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Oragenics Q2 2025 Shareholder UpdateAugust 11, 2025 | globenewswire.comOragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa TrialJuly 31, 2025 | finance.yahoo.comOragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical DevelopmentJuly 16, 2025 | globenewswire.comOragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants - Seeking AlphaJuly 3, 2025 | seekingalpha.comOragenics stock tumbles after announcing $20 million preferred stock offeringJuly 2, 2025 | investing.comOragenics Completes Approximately $16.5 Million OfferingJuly 2, 2025 | globenewswire.comOragenics shares plunge following announcement of $20 million preferred stock saleJuly 1, 2025 | msn.comOragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and WarrantsJuly 1, 2025 | globenewswire.comOragenics, Inc. to Present ONP-002 at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society SymposiumJune 11, 2025 | nasdaq.comOragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society SymposiumJune 10, 2025 | finance.yahoo.comOragenics (NYSE:OGEN) Trading Down 4.6% - Time to Sell?June 6, 2025 | marketbeat.comOragenics Inc.June 4, 2025 | wsj.comOragenics, Inc. Announces One-for-Thirty Reverse Stock SplitMay 29, 2025 | finance.yahoo.comOragenics Hosts Neurotrauma Medicine Webinar PresentationMay 20, 2025 | tipranks.comOragenics gains Australia’s nod for concussion therapy trialMay 15, 2025 | uk.investing.comOragenics, Inc. to Host Webinar on ONP-002 and Addressing Unmet Needs in Concussion TreatmentMay 14, 2025 | nasdaq.comOragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in AustraliaMay 13, 2025 | globenewswire.comOragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion ...May 12, 2025 | gurufocus.comOragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic VisionMay 12, 2025 | globenewswire.comOragenics Appoints Janet Huffman as CEO and CFOMay 2, 2025 | tipranks.comOragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference | OGEN ...April 23, 2025 | gurufocus.comOragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion TrialApril 9, 2025 | finance.yahoo.comOragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery SummitApril 7, 2025 | globenewswire.comOragenics provides Q1 shareholder update on strategic financial progressMarch 28, 2025 | markets.businessinsider.comOragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial ProgressMarch 27, 2025 | globenewswire.comOragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-KMarch 18, 2025 | globenewswire.comOragenics submits IB for Phase II clinical trial of ONP-002 in mTBIMarch 6, 2025 | markets.businessinsider.comOragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)March 6, 2025 | markets.businessinsider.comOragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)March 6, 2025 | globenewswire.comOragenics CMO to present at Emergencies in Medicine ConferenceFebruary 25, 2025 | markets.businessinsider.comOragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion TreatmentFebruary 25, 2025 | globenewswire.comOragenics announces partnership with BRAINBox SolutionsFebruary 11, 2025 | markets.businessinsider.comOragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and TreatmentFebruary 11, 2025 | globenewswire.comOragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025February 5, 2025 | globenewswire.comOragenics appoints Huffman as interim CEO, provides shareholder updateJanuary 22, 2025 | markets.businessinsider.comOragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEOJanuary 21, 2025 | globenewswire.comOragenics appoints interim CEO, ups CFO salaryJanuary 17, 2025 | msn.comOragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation PreferenceDecember 16, 2024 | globenewswire.comOragenics announces termination of president's employment agreementDecember 1, 2024 | investing.comOragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas SummitOctober 18, 2024 | globenewswire.comOragenics inks sales agreement for at-the-market stock offeringOctober 17, 2024 | investing.comBioMedNewsBreaks — Oragenics, Inc. (NYSE American: OGEN) Reports on Lead Candidate Drug Development, ‘Urgency’ to Advance First-in-Class Concussion TreatmentOctober 9, 2024 | msn.comOragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial PreparationOctober 9, 2024 | globenewswire.comInvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Advances Concussion Treatment with Promising Study for Nasal Spray Drug ONP-002October 8, 2024 | msn.comEXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug CandidateOctober 8, 2024 | benzinga.comOragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002October 8, 2024 | globenewswire.comCore One Labs Inc. (LD6.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comOragenics, Inc. Announces Closing of Public OfferingSeptember 5, 2024 | globenewswire.comBioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Enters into Public Offering Agreement Estimated to Total $4.45MSeptember 4, 2024 | msn.comWhy Oragenics (OGEN) Stock Is Getting HammeredSeptember 4, 2024 | benzinga.com Get Oragenics News Delivered to You Automatically Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OGEN Media Mentions By Week OGEN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OGEN News Sentiment▼0.001.03▲Average Medical News Sentiment OGEN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OGEN Articles This Week▼01▲OGEN Articles Average Week Get the Latest News and Ratings for OGEN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Oragenics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Promis Neurosciences News Today Chemomab Therapeutics News Today Moleculin Biotech News Today X4 Pharmaceuticals News Today LakeShore Biopharma News Today Edesa Biotech News Today Hoth Therapeutics News Today Lixte Biotechnology News Today Lipocine News Today NeuroSense Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:OGEN) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access